Clinical trials: Choroidal Neovascularization
Wet Macular Degeneration
Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
The addition of an anti-inflammatory agent could be a valid option for controlling choroidal neovascularization, as simply inhibiting VEGF addresses neither the multifactorial pathogenesis of choroidal neovascularization nor the…
- Trial name
- NCT02060604
- Testing
- Ketorolac + Ranibizumab, Ranibizumab
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Università degli Studi di Brescia
Wet Macular Degeneration
Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
The purpose of this study is to evaluate the effects and safety of ranibizumab therapy combined with TA versus ranibizumab monotherapy in patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- RANTA (NCT02806752)
- Testing
- Triamcinolone Acetonide, Ranibizumab
- Where
- 7 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Aier School of Ophthalmology, Central South University
Polypoidal Choroidal Vasculopathy
Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment
In this study, we aim to evaluate the efficacy and safety of an individualized dosing schedule comprising Aflibercept and RF-PDT in patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- NCT03941587
- Testing
- Aflibercept + reduced fluence photodynamic therapy (RF-PDT)
- Where
- 2 sites in Singapore
- Volunteers
- 60 people
- Sponsor
- Singapore National Eye Centre
Inflammatory Choroidal Neovascularization
Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory CNV in Young Patients (ALINEA).
Inflammatory choroidal neovascularization (InCNV) is the third cause of CNV after myopia and Age-related Macular Degeneration (AMD). InCNV is a rare but severe disease and its treatment should not be delayed.
- Trial name
- ALINEA (NCT02556229)
- Testing
- Aflibercept
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects…
- Trial name
- NCT01940887
- Testing
- E10030, bevacizumab or aflibercept
- Where
- 207 sites in United States, Argentina and 20 more
- Volunteers
- 645 people
- Sponsor
- Ophthotech Corporation
Choroidal Neovascularization
Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization
The objectives of this study are to investigate the safety and effectiveness of EYLEA.
- Trial name
- NCT02260687
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 353 people
- Sponsor
- Bayer
Macular Degeneration
Ranibizumab and Reduced Fluence PDT for AMD
Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration.
- Trial name
- RAP (NCT00527475)
- Testing
- ranibizumab, verteporfin
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Texas Retina Associates
Exudative Age-related Macular Degeneration
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD).
- Trial name
- Nexus (NCT01414153)
- Testing
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
- Where
- 44 sites in United States
- Volunteers
- 158 people
- Sponsor
- Lpath, Inc.
Choroidal Neovascularization
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
This research is being done to look at the effects of an experimental drug, ranibizumab, on a condition called "predominantly hemorrhagic subfoveal choroidal neovascularization (CNV)" due to wet age-related macular degeneration.
- Trial name
- NCT00363168
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Johns Hopkins University
Choroidal Neovascularization, Punctate Inner Choroidopathy
Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor
To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after anti-vascular endothelial factor treatment.
- Trial name
- NCT03793400
- Testing
- Bevacizumab Injection
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- Changhua Christian Hospital
Nearsightedness
Effect of Defocus in Soft Contact Lenses on Internal Retinal Vascularization
The purpose of this study is to gain a better understanding of the retinal vascular changes that occur in response to the optical effect of a myopic defocus daily disposable soft contact lens (MDSL) in a group of healthy young…
- Trial name
- NCT06527274
- Testing
- Experimental: Myopic defocus soft lens design (MDSL), Active Comparator: Single vision soft lens design (SVSL
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Université de Montréal
Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
To evaluate and compare two individualised ranibizumab treatment regimens, differentiated by the definition of disease activity, which determines the treatment interval until the next injection.
- Trial name
- FLUID (NCT01972789)
- Testing
- Ranibizumab
- Where
- 16 sites in Australia
- Volunteers
- 349 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration
Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion
The purpose of the present study was to evaluate the proportion of eyes that do not meet the eligibility criteria of clinical trials on neovascular AMD among the entire sample of eyes diagnosed with treatment-naïve neovascular…
- Trial name
- NCT04836143
- Testing
- Intravitreal anti-vascular endothelial growth factor injection
- Where
- South Korea
- Volunteers
- 512 people
- Sponsor
- Kim's Eye Hospital
Age Related Macular Degeneration
Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
The study will test if the efficacy and safety of an alternative dosing regimen is as effective as monthly injections.
- Trial name
- EXCITE (NCT00275821)
- Testing
- Ranibizumab 0.3 mg - 3 times monthly, then quarterly, Ranibizumab 0.5 mg - 3 times monthly, then quarterly, Ranibizumab 0.3 mg monthly
- Where
- Switzerland
- Volunteers
- 353 people
- Sponsor
- Novartis
Age-Related Macular Degeneration
Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab
To determine if patients treated early after diagnosis of wet age-related macular degeneration can return/maintain to their baseline pre-disease BCVA.
- Trial name
- COMPASS (NCT01402544)
- Testing
- ranibizumab
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Diego
Punctate Inner Choroidopathy
Long-term Outcome of Zonal Outer Retinopathy in Punctate Inner Choroidopathy or Multifocal Choroiditis
To report the long term prognosis in patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) and associated zonal outer retinopathy (ZOR).
- Trial name
- NCT03897192
- Testing
- Bevacizumab
- Where
- Taiwan
- Volunteers
- 14 people
- Sponsor
- Changhua Christian Hospital
Macular Degeneration
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
This study will test the safety and effectiveness of combining a laser treatment called photodynamic therapy, or PDT, with injections into the eye of the steroid triamcinolone acetonide for treating age-related macular…
- Trial name
- NCT00100009
- Testing
- TAC-PF, Triamcinolone Acetonide
- Where
- 23 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Eye Institute (NEI)
Age Related Macular Degeneration
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
This study is an evaluation of the short term effects on CNV perfusion of a same-day administration of photodynamic therapy (PDT) with Visudyne® and an intravitreal injection of Lucentis® (ranibizumab, 0.3 mg).
- Trial name
- NCT00413829
- Testing
- Intravitreal ranibizumab with photodynamic therapy
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Macular Degeneration
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor's other clinical studies with this drug for AMD, until…
- Trial name
- NCT00088192
- Testing
- pegaptanib sodium
- Where
- 20 sites in United States
- Sponsor
- Eyetech Pharmaceuticals
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy
Study the effectiveness of the treatment detachment of retinal pigment epithelium secondary to polypoidal choroidal vasculopathy. Efficacy will be assessed by regression of polyp area after twelve months, compared to baseline.
- Trial name
- NCT01666236
- Testing
- Triple Therapy
- Where
- Brazil
- Sponsor
- Federal University of São Paulo